Literature DB >> 8825884

Adult fragile X syndrome: neuropsychology, brain anatomy, and metabolism.

M B Schapiro1, D G Murphy, R J Hagerman, N P Azari, G E Alexander, C M Miezejeski, V J Hinton, B Horwitz, J V Haxby, A Kumar.   

Abstract

To understand the implications of suboptimal gene expression in fragile X syndrome -fra(X)-, we sought to define the central nervous abnormalities in fra(X) syndrome to determine if abnormalities in specific brain regions or networks might explain the cognitive and behavioral abnormalities in this syndrome. Cranial and ventricular volumes were measured with quantitative computed tomography (CT), regional cerebral metabolic rates for glucose (rCMRglc) were measured with [18-F]-2-fluoro-2-deoxy-D-glucose (18FDG), and patterns of cognition were determined with neuropsychological testing in ten healthy, male patients with karyotypically proven fra(X) syndrome (age range 20-30 yr). Controls for the CT studies were 20 healthy males (age range 21-37 yr), controls for the PET studies were 9 healthy males (age range 22-31 yr), and controls for the neuropsychological tests were 10 young adult, male Down syndrome (DS) subjects (age range 22-31 yr). The mean mental age of the fra(X) syndrome group was 5.3 yr (range 3.5-7.5 yr; Stanford-Binet Intelligence Scale). Despite comparable levels of mental retardation, the fra(X) subjects showed poorer attention/short term memory in comparison to the DS group. Further, the fra(X) subjects showed a relative strength in verbal compared to visuospatial attention/short term memory. As measured with quantitative CT, 8 fra(X) subjects had a significant (P < 0.05) 12% greater intracranial volume (1,410 +/- 86 cm3) as compared to controls (1,254 +/- 122 cm3). Volumes of the right and left lateral ventricles and the third ventricle did not differ between groups. Seven of eight patients had greater right lateral ventricle volumes than left, as opposed to 9 out of 20 controls (P < 0.05). Global gray matter CMR-glc in nine fra(X) patients was 9.79 +/- 1.28 mg/100 g/minute and did not differ from 8.84 +/- 1.31 mg/100 g/minute in the controls. R/L asymmetry in metabolism of the superior parietal lobe was significantly higher in the patients than controls. A preliminary principal component analysis of metabolic data showed that the fra(X) subjects tended to form a separate subgroup that is characterized by relative elevation of normalized metabolism in the lenticular nucleus, thalamus, and premotor regions. Further, a discriminant function, that reflected rCMRglc interactions of the right lenticular and left premotor regions, distinguished the fra(X) subjects from controls. These regions are part of a major group of functionally and anatomically related brain regions and appear disturbed as well in autism with which fra(X) has distinct behavioral similarities. These results show a cognitive profile in fra(X) syndrome that is distinct from that of Down syndrome, that the larger brains in fragile X syndrome are not accompanied by generalized cerebral cortical atrophy or hypoplasia, and that distinctive alterations in resting regional glucose metabolism, measured with 18 FDG and PET, occur in fra(X) syndrome.

Entities:  

Mesh:

Year:  1995        PMID: 8825884     DOI: 10.1002/ajmg.1320600603

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  20 in total

1.  Abnormal development of dendritic spines in FMR1 knock-out mice.

Authors:  E A Nimchinsky; A M Oberlander; K Svoboda
Journal:  J Neurosci       Date:  2001-07-15       Impact factor: 6.167

2.  Elevated glycogen synthase kinase-3 activity in Fragile X mice: key metabolic regulator with evidence for treatment potential.

Authors:  Wenzhong William Min; Christopher J Yuskaitis; Qijiang Yan; Christopher Sikorski; Shengqiang Chen; Richard S Jope; Robert P Bauchwitz
Journal:  Neuropharmacology       Date:  2008-10-14       Impact factor: 5.250

3.  Neuroanatomical abnormalities in fragile X syndrome during the adolescent and young adult years.

Authors:  Gisela M Sandoval; Sehoon Shim; David S Hong; Amy S Garrett; Eve-Marie Quintin; Matthew J Marzelli; Swetapadma Patnaik; Amy A Lightbody; Allan L Reiss
Journal:  J Psychiatr Res       Date:  2018-10-25       Impact factor: 4.791

Review 4.  Fragile X syndrome. Molecular and clinical insights and treatment issues.

Authors:  R J Hagerman
Journal:  West J Med       Date:  1997-02

5.  Working memory subsystems and task complexity in young boys with Fragile X syndrome.

Authors:  S Baker; S Hooper; M Skinner; D Hatton; J Schaaf; P Ornstein; D Bailey
Journal:  J Intellect Disabil Res       Date:  2010-12-01

Review 6.  Fragile X-associated disorders: a clinical overview.

Authors:  Anne Gallagher; Brian Hallahan
Journal:  J Neurol       Date:  2011-07-12       Impact factor: 4.849

7.  Increased rates of cerebral glucose metabolism in a mouse model of fragile X mental retardation.

Authors:  Mei Qin; Julia Kang; Carolyn Beebe Smith
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-11       Impact factor: 11.205

Review 8.  Neuroimaging endophenotypes in animal models of autism spectrum disorders: lost or found in translation?

Authors:  Marija M Petrinovic; Basil Künnecke
Journal:  Psychopharmacology (Berl)       Date:  2013-07-14       Impact factor: 4.530

Review 9.  Oxytocin and vasopressin systems in genetic syndromes and neurodevelopmental disorders.

Authors:  S M Francis; A Sagar; T Levin-Decanini; W Liu; C S Carter; S Jacob
Journal:  Brain Res       Date:  2014-01-22       Impact factor: 3.252

Review 10.  The FMR1 gene and fragile X-associated tremor/ataxia syndrome.

Authors:  J R Brouwer; R Willemsen; B A Oostra
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2009-09-05       Impact factor: 3.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.